Sermorelin / Ipamorelin Blend
Also known as: Sermorelin & Ipamorelin, Sermorelin + Ipamorelin Blend
A widely studied research blend combining the GHRH analog Sermorelin with the highly selective ghrelin-receptor agonist Ipamorelin. It is examined for clean, synergistic growth hormone release with minimal off-target effects.
Last updated
Mechanism of Action
Sermorelin (GHRH 1-29) stimulates the pituitary GHRH receptor to drive growth hormone synthesis and pulsatile release. Ipamorelin is a selective GHS-R1a (ghrelin) receptor agonist that triggers an additional GH pulse without meaningfully elevating cortisol, prolactin, or aldosterone, giving it a cleaner profile than older GHRPs. Acting on two separate receptors, the pair produces a synergistic GH response while preserving physiologic feedback and the natural pulsatile pattern.
- Half-life
- Mixed: Sermorelin ~10-20 minutes, Ipamorelin ~2 hours
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Studied for synergistic and selective GH release
- Investigated for minimal cortisol and prolactin elevation
- Examined for improved lean mass and recovery
- Researched for enhanced slow-wave sleep quality
- Studied for IGF-1 elevation through natural pituitary signaling
- Investigated for support of fat metabolism
Potential Side Effects
- Injection-site redness or transient swelling
- Mild water retention or tingling in extremities
- Transient flushing or lightheadedness after injection
- Mild headache or fatigue
- Modest appetite increase
Common Dosing
In the research literature, blends are studied at approximately 100-300 mcg of each component per administration, 1-2 times daily, often pre-sleep or fasted. For research-use only; not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy or history of cancer
- Pregnancy or breastfeeding
- Known hypersensitivity to GHRH or ghrelin-receptor analogs
Sermorelin / GHRP-2 Blend
A research blend pairing the GHRH analog Sermorelin with the growth hormone-releasing peptide GHRP-2. The combination is studied for synergistic stimulation of endogenous growth hormone.
Sermorelin / GHRP-6 Blend
A research blend combining the GHRH analog Sermorelin with the ghrelin-receptor agonist GHRP-6. It is studied for synergistic growth hormone release and appetite stimulation.
CJC-1295 (No DAC) / Ipamorelin / GHRP-2 Blend
This three-peptide blend pairs CJC-1295 without DAC (a GHRH analog) with two ghrelin-mimetic secretagogues, Ipamorelin and GHRP-2, to maximize a clean, synergistic growth hormone pulse. All components are unapproved research peptides.
- View
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
1999
- View
Ipamorelin, the first selective growth hormone secretagogue
1998
- View
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
1999
- View
GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers
1995
- View
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
2006